This case study describes a de-identification project conducted with Sanofi Pasteur and Sanofi to de-identify a vaccine clinical trial dataset using the Privacy Analytics methodology and software, to compare its results with Sanofi’s current process, and inform Sanofi’s de-identification methodology.
Sanofi has a number of initiatives to share clinical trial data with the research community for secondary purposes. Maximizing the utility of clinical trial participant data provides opportunities to conduct further research, help advance medical science and improve patient care.
Sanofi is not alone in this drive to share clinical trial data. There is a growing movement to increase the sharing of clinical trial data by researchers and manufacturers. As manufacturers start to make individual participant data (IPD) from their clinical trials available, privacy concerns must be addressed.
